<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="8341">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02047604</url>
  </required_header>
  <id_info>
    <org_study_id>C2013-0302</org_study_id>
    <secondary_id>2013-003719-23</secondary_id>
    <nct_id>NCT02047604</nct_id>
  </id_info>
  <brief_title>(C2013-0302) Safety and Efficacy of Escalating Doses of SAN-300 in Patients With Rheumatoid Arthritis</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Escalating Doses of SAN-300 in Patients With Active Rheumatoid Arthritis With Inadequate Response to Disease-Modifying Anti-rheumatic Drug(s).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Salix Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Salix Pharmaceuticals</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>Ukraine: Ministry of Health</authority>
    <authority>Russia: Ministry of Health of the Russian Federation</authority>
    <authority>Czech Republic: State Institute for Drug Control</authority>
    <authority>Romania: National Medicines Agency</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of
      Escalating Doses of SAN-300 in Patients with Active Rheumatoid Arthritis with Inadequate
      Response to Disease-Modifying Anti-rheumatic Drug(s).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">January 2015</completion_date>
  <primary_completion_date type="Anticipated">January 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Incidence and severity of adverse events</measure>
    <time_frame>10 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Adverse events data are collected during a 10-week period, which includes 6 weeks of treatment and 4 weeks of follow-up.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease Activity Score (DAS) with 28-joint count using C-reactive protein</measure>
    <time_frame>Change from baseline to the End of Treatment Visit (Week 7)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>American College of Rheumatology 20 (ACR20) responder rate</measure>
    <time_frame>End of Treatment Visit (Week 7)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in the Health Assessment Questionnaire-Disease index (HAQ-DI)</measure>
    <time_frame>End of Treatment Visit (Week 7)</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>MRI findings of the hand and wrist</measure>
    <time_frame>End of Treatment Visit (Week 7)</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Cohort A</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>SAN-300 0.5 mg/kg subcutaneous once weekly for six weeks or placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>SAN-300 1.0 mg/kg subcutaneous once weekly for six weeks or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort C</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>SAN-300 2.0 mg/kg subcutaneous every other week for six weeks or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort D</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>SAN-300 2.0 mg/kg subcutaneous once weekly for six weeks or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort E</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>SAN-300 4.0 mg/kg subcutaneous every other week for six weeks or placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SAN-300</intervention_name>
    <arm_group_label>Cohort A</arm_group_label>
    <arm_group_label>Cohort B</arm_group_label>
    <arm_group_label>Cohort C</arm_group_label>
    <arm_group_label>Cohort D</arm_group_label>
    <arm_group_label>Cohort E</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Cohort A</arm_group_label>
    <arm_group_label>Cohort B</arm_group_label>
    <arm_group_label>Cohort C</arm_group_label>
    <arm_group_label>Cohort D</arm_group_label>
    <arm_group_label>Cohort E</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Diagnosed with RA for ≥ 6 months according to American College of Rheumatology
             (ACR)/European League Against Rheumatism (EULAR) Classification Criteria 2010

          2. 18 to 75 years of age, inclusive, at the time of informed consent

          3. Swollen joint count of ≥ 6 (66-joint count) and tender joint count of ≥ 6 (68-joint
             count) at Screening and randomization

          4. C-reactive protein (CRP) &gt; upper limit of normal (ULN)

          5. Inadequate response to therapy or discontinuation of therapy because of unacceptable
             toxicity from at least one prior traditional or biologic disease-modifying
             anti-rheumatic drug (DMARD) but not more than one biologic DMARD

          6. Stable dose of methotrexate (≥ 15 mg/week and ≤ 25 mg/week) for ≥ 6 weeks before
             randomization

        Exclusion Criteria:

          1. Functional Class IV as defined by ACR classification of functional status in RA

          2. History of significant systemic involvement secondary to RA (e.g., vasculitis,
             pulmonary fibrosis, or Felty's syndrome)

          3. History of malignancy or carcinoma in situ within the 5 years before Screening or any
             history of melanoma. Patients with history of excised or adequately treated
             non-melanoma skin cancer are eligible

          4. Evidence of clinically significant uncontrolled concurrent diseases such as
             cardiovascular, endocrinologic, hematologic, hepatic, immunologic, metabolic,
             urologic, pulmonary, neurologic, dermatologic, psychiatric, renal, and/or other major
             diseases

          5. History of recurrent clinically significant infections

          6. Current active infection or serious local infection (e.g., cellulitis, abscess) or
             systemic infection (e.g., pneumonia, septicemia) within 3 months before randomization

          7. History of severe allergic or anaphylactic reactions to other biologic agents

          8. History of allergies to murine protein

          9. Surgery within 3 months before randomization (other than minor cosmetic surgery or
             minor dental procedures) or plans for a surgical procedure during the Treatment
             Period or Follow-up Period

         10. History of tuberculosis or latent infection currently undergoing treatment

         11. History of malaria

         12. Prior treatment with more than one biologic DMARD

         13. Treatment regimen with prednisone that is either over 10 mg/day (or equivalent dose
             of another corticosteroid) or is not taken at a stable dose of ≤ 10 mg/day for at
             least 4 weeks before randomization

         14. Intra-articular corticosteroid injection(s) within 4 weeks before randomization

         15. Any live immunization/vaccination, including against Herpes zoster, within 4 weeks
             before randomization. Live vaccinations must also be avoided throughout the study

         16. Abnormal laboratory value at Screening or Day -1 considered clinically significant

         17. Positive for hepatitis C virus (HCV) antibody or hepatitis B surface antigen (HBsAg)

         18. Positive for human immunodeficiency virus (HIV) antibody

         19. History of tuberculosis or positive QuantiFERON®-TB Gold test (QFT)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Betsy P. Smith-Edwards, RN, BSN</last_name>
    <phone>919 800 4980</phone>
    <email>betsy.smith-edwards@salix.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Santarus Clinical Investigational Site 1005</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35216</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Santarus Clinical Investigational Site 1004</name>
      <address>
        <city>El Cajon</city>
        <state>California</state>
        <zip>92020</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Santarus Clinical Investigational Site 1002</name>
      <address>
        <city>Edgewater</city>
        <state>Florida</state>
        <zip>32132</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Santarus Clinical Investigational Site 1003</name>
      <address>
        <city>Palm Harbor</city>
        <state>Florida</state>
        <zip>34684</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Santarus Clinical Investigational Site 1007</name>
      <address>
        <city>Reno</city>
        <state>Nevada</state>
        <zip>89502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Santarus Clinical Investigational Site 1006</name>
      <address>
        <city>Salisbury</city>
        <state>North Carolina</state>
        <zip>28144</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Santarus Clinical Investigational Site 1001</name>
      <address>
        <city>Middleburg Heights</city>
        <state>Ohio</state>
        <zip>44130</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 14, 2014</lastchanged_date>
  <firstreceived_date>January 22, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phase 2a multiple ascending dose, Anti-Very Late Antigen-1</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Antirheumatic Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
